NOA

Edit Your Profile

NOA Journal

publication venue for

Metabolomic profiling and stable isotope tracing of human schwannomas: A novel perspective on tumor biology and radiation response. vdaf223. 2025
CTLT-04 SAFETY AND PRELIMINARY EVIDENCE OF A THERAPEUTIC EFFECT OF AZELIRAGON COMBINED WITH STEREOTACTIC RADIATION THERAPY IN PATIENTS WITH BRAIN METASTASES: PHASE 1 STUDY RESULTS. 7:ii8-ii8. 2025
MMOD-14 IMPACT OF SYSTEMIC THERAPY ACTIVITY ON BRAIN METASTASIS OUTCOMES IN A FEMALE AND HISPANIC-DOMINANT LUNG CANCER COHORT TREATED WITH STEREOTACTIC RADIOSURGERY. 6:i18-i19. 2024
NIRL-04 BRAIN METASTASES DISTRIBUTION WIDTH (BMDW): A NOVEL METRIC TO PREDICT DISTANT BRAIN FAILURE FOLLOWING STEREOTACTIC RADIOSURGERY IN PATIENTS WITH MULTIPLE BRAIN METASTASES. 6:i20-i21. 2024
NIRL-11 3D-FSE IMAGING FOR RADIOSURGERY PLANNING IMPROVES BRAIN METASTASIS DETECTION AND REDUCES INTRACRANIAL RELAPSE. 6:i22-i22. 2024
CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS. 5:iii8-iii8. 2023
NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH18F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY. 5:iii14-iii15. 2023
CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER. 4:i8-i8. 2022
SPIN-01 RADIATION THERAPY ALONE VERSUS RADIATION THERAPY PLUS RADIOFREQUENCY ABLATION/VERTEBRAL AUGMENTATION FOR SPINE METASTASIS: TRIAL IN PROGRESS. 4:i11-i11. 2022
SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS. 4:i24-i24. 2022
OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. 3:iii15-iii16. 2021
RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. 3:iii20-iii20. 2021
30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL. 2:ii5-ii5. 2020
33. SYSTEMATIC REVIEW AND META-ANALYSIS OF BREAST CANCER BRAIN METASTASIS AND PRIMARY TUMOR RECEPTOR EXPRESSION DISCORDANCE. 2:ii6-ii6. 2020
RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933. 1:i22-i22. 2019
RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM). 1:i23-i24. 2019
TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL. 1:i8-i8. 2019
TRLS-09. RTOG1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY / STEREOTACTIC RADIOSURGERY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER. 1:i10-i10. 2019

International Standard Serial Number (ISSN)

0801-3284